“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.
Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.